No Prescription |
 |
 | ||
|
RALISTA Evista |
|
| ||
No Prescription » Prescription Drugs 14 » RALISTA Evista Raloxifene is used for: Treating and preventing osteoporosis (bone thinning) in women past menopause. Ralista is prescribed to treat and prevent osteoporosis the brittle-bone disease that strikes some women after menopause. A variety of factors promote osteoporosis. The more factors that apply to you the greater your chances of developing the disease. These factors include:Caucasian or Asian descentSlender buildEarly menopauseSmokingDrinkingA diet low in calciumAn inactive lifestyleOsteoporosis in the familyRaloxifene affects the cycle of bone formation and breakdown in the body and reduces loss of bone tissue. Raloxifene is used to treat or prevent osteoporosis in postmenopausal women. Raloxifene is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are otherwise at risk of invasive breast cancer. Buy RALISTA Evista and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About RALISTA Evista: Product Type: Prescription Drugs 14 RALISTA ( Evista Generic Raloxifene ) RALISTA (Evista Generic Raloxifene) Evista Generic Raloxifene 60mg Evista Generic Raloxifene RALISTA
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
